Enovix (NASDAQ:ENVX) Updates Q1 2026 Earnings Guidance

Enovix (NASDAQ:ENVX) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of -0.180–0.140 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $6.5 million-$7.5 million, compared to the consensus revenue estimate of $8.8 million.

Enovix Stock Up 0.7%

NASDAQ:ENVX traded up $0.04 during trading hours on Wednesday, hitting $6.15. 7,620,218 shares of the stock traded hands, compared to its average volume of 6,354,530. The firm has a 50 day moving average price of $7.21 and a 200 day moving average price of $8.98. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -7.59 and a beta of 2.13. The company has a current ratio of 9.72, a quick ratio of 9.47 and a debt-to-equity ratio of 1.74. Enovix has a fifty-two week low of $5.27 and a fifty-two week high of $16.49.

Enovix (NASDAQ:ENVX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Enovix had a negative return on equity of 61.78% and a negative net margin of 525.93%.Enovix has set its Q1 2026 guidance at -0.180–0.140 EPS. Equities research analysts anticipate that Enovix will post -1.01 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ENVX. JPMorgan Chase & Co. lowered their price target on Enovix from $12.00 to $10.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 12th. Oppenheimer set a $24.00 price objective on Enovix in a research report on Thursday, November 6th. Northland Securities set a $16.00 price target on shares of Enovix in a research report on Monday, November 17th. Canaccord Genuity Group dropped their price objective on Enovix from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enovix in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC grew its position in shares of Enovix by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock valued at $39,000 after buying an additional 1,342 shares during the last quarter. Mackenzie Financial Corp bought a new position in Enovix during the fourth quarter worth $77,000. CIBC Asset Management Inc acquired a new stake in shares of Enovix in the 4th quarter valued at about $78,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Enovix during the third quarter valued at approximately $80,000. Finally, Cibc World Markets Corp bought a new stake in Enovix during the 4th quarter valued at $82,000. 50.92% of the stock is currently owned by institutional investors.

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.